2008: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's: Pathogenesis, Animal Models, and Genetics I
Search or Browse by Day

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's: Pathogenesis, Animal Models, and Genetics I

Monday, October 27, 2008
1129
Hepatocyte Growth Factor Promoter Gene Polymorphism Controls Severity of Interstitial Lung Disease in Patients with Systemic Sclerosis
1130
A Large multicenter analysis of CTGF -945 promoter polymorphism does not confirm association with Systemic Sclerosis susceptibility or phenotype
1131
Association of IL1A Promoter Polymorphism with Systemic Sclerosis
1132
Association of FCRL3 Promoter Polymorphism with Systemic Sclerosis
1133
Peripheral Blood Cell (PBC) Gene Expression Profiles of Systemic Sclerosis and its Serological Subtypes
1134
A Single Nucleotide Polymorphism Associated with Expression of Interferon Regulatory Factor 5 (IRF5) is a Genetic Risk Factor for Systemic Sclerosis
1135
The PTPN22 620W allele confers susceptibility to Systemic Sclerosis: a large case control study among European Caucasians and meta-analysis
1136
Association of Interleukin-10 Receptor 2 Gene (IL10RB) Polymorphisms with Diffuse Cutaneous Systemic Sclerosis
1137
Analysis of Polymorphisms in the Endothelin Axis in Patients with Raynaud’s Phenomenon and Erythromelalgia
1138
Global gene expression changes induced by Allograft Inflammatory Factor-1 expression in primary vascular endothelial cells
1139
Activation of the Type I IFN Pathway in Systemic Sclerosis (SSc) is detected at the level of PBMC Gene Expression: Association with Higher Skin Scores, Inflammatory Markers and anti-Ro Antibodies
1140
The Role of HLA-B35 in Endothelial Cell Dysfunction
1141
Reproducible And Stable Gene Expression Subsets In Serial Skin Biopsies From Patients Treated In An Open-label Trial Of Rituximab
1142
Association of an Estrogen-Related Receptor Gamma (ESRRG) Polymorphism with Systemic Sclerosis
1143
Disturbed Angiogenesis In Systemic Sclerosis: Impaired Expression Of VEGFR1 In Endothelial Progenitor Derived Cells Under Hypoxic Conditions
1144
Novel Autoantibodies to High Mobility Group Box 1 Protein in Localized Scleroderma
1145
Increased frequency of T regulatory cells in Systemic Sclerosis displaying a markedly altered phenotype and compromised regulatory capacity
1146
Anti-fibrogenic Effect Of Thalidomide Through Inhibiting Tgf-β-induced Jnk-1 And Erk Pathway And Enhancing Caveolin-1 In Bleomycin-induced Pulmonary Fibrosis In Mice
1147
Investigation Of The Role Of Rac1 In A Bleomycin-induced Scleroderma Model Using Fibroblast-specific Rac1 Knockout Mice
1148
Naturally-Acquired Microchimerism in Systemic Sclerosis
1149
Role of Vγ9+ γδ T cells in progressive systemic sclerosis (PSS)
1150
MicroRNA 29a - a Critical Regulator of Fibrotic Mechanisms in SSc
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>